Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Catherine M Albert

Showing results (21-30 of 33) with videos related to

Pageof 4
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 10, 2024
STRIvE-02: A First-in-Human Phase I Study of Systemically Administered B7-H3 Chimeric Antigen Receptor T Cells for Patients With Relapsed/Refractory Solid TumorsNavin Pinto, Catherine M Albert, Mallory R Taylor, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 18, 2026
The first-in-human ENCIT01 trial comparing second- versus third-generation L1CAM-specific CAR T cells in patients with primary refractory or relapsed neuroblastomaNavin Pinto, Annette Künkele, Catherine M Albert, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 27, 2025
Elective Discontinuation of Larotrectinib in Pediatric Patients With TRK Fusion Sarcomas and Related Mesenchymal TumorsLeo Mascarenhas, Steven G DuBois, Catherine M Albert, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 3, 2025
Erratum: Elective Discontinuation of Larotrectinib in Pediatric Patients With TRK Fusion Sarcomas and Related Mesenchymal TumorsLeo Mascarenhas, Steven G DuBois, Catherine M Albert, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 14, 2025
Erratum: Elective Discontinuation of Larotrectinib in Pediatric Patients With TRK Fusion Sarcomas and Related Mesenchymal TumorsLeo Mascarenhas, Steven G DuBois, Catherine M Albert, et al.
Neuro-Oncology|March 12, 2025
Locoregional Infusion of EGFR806-CAR T Cells for Recurrent or Refractory Pediatric CNS Tumors: Results of the Completed BrainChild02 Phase 1 Clinical TrialJuliane Gust, Bonnie L Cole, Rebecca Ronsley, et al.
NPJ Precision Oncology|May 5, 2026
An international framework for clinical translation of molecular classifiers in osteosarcomaAmanda E Marinoff, Michaela Nathrath, David S Shulman, et al.
The Lancet. Oncology|February 28, 2020
Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1/2 clinical trialsDavid S Hong, Steven G DuBois, Shivaani Kummar, et al.
American Journal of Medical Genetics. Part A|June 6, 2020
Activating variants in PDGFRB result in a spectrum of disorders responsive to imatinib monotherapyTara L Wenger, Randall A Bly, Natalie Wu, et al.
Genetics in Medicine Open|November 1, 2024
Clinical RNA sequencing clarifies variants of uncertain significance identified by prior testingJonathan Marquez, Jennifer N Cech, Cate R Paschal, et al.
Pageof 4

Showing results (21-30 of 33) with videos related to

Sort By:
Pageof 4
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 10, 2024
STRIvE-02: A First-in-Human Phase I Study of Systemically Administered B7-H3 Chimeric Antigen Receptor T Cells for Patients With Relapsed/Refractory Solid TumorsNavin Pinto, Catherine M Albert, Mallory R Taylor, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 18, 2026
The first-in-human ENCIT01 trial comparing second- versus third-generation L1CAM-specific CAR T cells in patients with primary refractory or relapsed neuroblastomaNavin Pinto, Annette Künkele, Catherine M Albert, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 27, 2025
Elective Discontinuation of Larotrectinib in Pediatric Patients With TRK Fusion Sarcomas and Related Mesenchymal TumorsLeo Mascarenhas, Steven G DuBois, Catherine M Albert, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|March 3, 2025
Erratum: Elective Discontinuation of Larotrectinib in Pediatric Patients With TRK Fusion Sarcomas and Related Mesenchymal TumorsLeo Mascarenhas, Steven G DuBois, Catherine M Albert, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 14, 2025
Erratum: Elective Discontinuation of Larotrectinib in Pediatric Patients With TRK Fusion Sarcomas and Related Mesenchymal TumorsLeo Mascarenhas, Steven G DuBois, Catherine M Albert, et al.
Neuro-Oncology|March 12, 2025
Locoregional Infusion of EGFR806-CAR T Cells for Recurrent or Refractory Pediatric CNS Tumors: Results of the Completed BrainChild02 Phase 1 Clinical TrialJuliane Gust, Bonnie L Cole, Rebecca Ronsley, et al.
NPJ Precision Oncology|May 5, 2026
An international framework for clinical translation of molecular classifiers in osteosarcomaAmanda E Marinoff, Michaela Nathrath, David S Shulman, et al.
The Lancet. Oncology|February 28, 2020
Larotrectinib in patients with TRK fusion-positive solid tumours: a pooled analysis of three phase 1/2 clinical trialsDavid S Hong, Steven G DuBois, Shivaani Kummar, et al.
American Journal of Medical Genetics. Part A|June 6, 2020
Activating variants in PDGFRB result in a spectrum of disorders responsive to imatinib monotherapyTara L Wenger, Randall A Bly, Natalie Wu, et al.
Genetics in Medicine Open|November 1, 2024
Clinical RNA sequencing clarifies variants of uncertain significance identified by prior testingJonathan Marquez, Jennifer N Cech, Cate R Paschal, et al.
Pageof 4